comparemela.com

Latest Breaking News On - இதயம் தாளம் - Page 15 : comparemela.com

Dr Andrea Natale Helps Pioneer an Exciting New Treatment for Atrial Fibrillation

(Photo : Dr. Andrea Natale) On August 5, 2020 a major breakthrough was made in the treatment of atrial fibrillation (AFib) that could change the future of how practitioners reduce one of the most prevalent causes of strokes. Nearly simultaneously, a new device called the WATCHMAN FLX TM Left Atrial Appendage Closure was implanted into patients in Austin, Texas, and Thousand Oaks, California. The surgeries were led by Dr. Andrea Natale and Dr. Saibal Kar in California and Dr. Rodney Horton in Texas. This was the first FDA-approved implantation device for reducing strokes in patients with non-ventricular atrial fibrillation. What Is Atrial Fibrillation?

Cardiac wearables, iRhythm under cloud as reimbursement questions linger

First published on While attention focused on iRhythm Technologies after Medicare rates for long-term cardiac monitoring were slashed in January, the fallout is now extending to other players and the future of the much-hyped market is being questioned. Novitas Solutions, which sets regional Medicare rates as a Medicare Administrative Contractor, is working with iRhythm and rivals about possibly changing the published rates. However, there is no timetable for when or if the rates will change, leaving Wall Street and industry in a holding pattern. Baird Equity Research analyst Mike Polark said that the reimbursement uncertainty makes any long-term growth expectation for iRhythm and the overall cardiac wearables market difficult.

Cardiac wearables, iRhythm, under a cloud as reimbursement questions linger

Share it While attention focused on iRhythm Technologies after Medicare rates for long-term cardiac monitoring were slashed in January, the fallout is now extending to other players and the future of the much-hyped market is being questioned. Novitas Solutions, which sets regional Medicare rates as a Medicare Administrative Contractor, is working with iRhythm and rivals about possibly changing the published rates. However, there is no timetable for when or if the rates will change, leaving Wall Street and industry in a holding pattern. Baird Equity Research analyst Mike Polark said that the reimbursement uncertainty makes any long-term growth expectation for iRhythm and the overall cardiac wearables market difficult.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.